North America Jan 25, 2023 Tango Therapeutics Gets FDA Permission to Start Studying PRMT5 Inhibitor in MTAP-Deleted Cancers Jan 25, 2023 Verastem Oncology Plans for FDA Submission of Avutometinib-Defactinib Combo in Ovarian Cancer Jan 24, 2023 ImmPact Bio to Begin Phase I/II Trial of Bispecific CAR T-Cell Therapy in Aggressive Lymphoma Jan 24, 2023 Geneoscopy Submits PMA Application to FDA for Stool-Based Colorectal Cancer Screening Test Jan 24, 2023 Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test Jan 23, 2023 Viewpoint Molecular Targeting Treats First Neuroendocrine Cancer Patients With Radiopharmaceutical Jan 23, 2023 Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment Jan 20, 2023 Astellas' Zolbetuximab Plus Chemo Benefits CLDN18.2-Positive, HER2-Negative Gastric Cancer Patients Premium Jan 20, 2023 Mirati Therapeutics' KRAS G12D Inhibitor Cleared by FDA to Begin Phase I/II Trial Jan 19, 2023 Colorectal Cancer Detection Data from CellMax Life Bodes Well for Planned FDA Bid Premium Jan 19, 2023 Gene Signature Beats TILs as Biomarker of Response to Anti-HER2 Therapy Premium Jan 19, 2023 Liquid Biopsy Biomarker Score Predicts Relapse in Lymphoma Patients After CAR T-Cell Treatment Premium Jan 19, 2023 Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug Jan 19, 2023 Caris Life Sciences Raises $400M in Senior Secured Debt Financing Jan 18, 2023 Freenome Partners With Geisinger to Recruit Patients for Multi-Cancer Screening Study Jan 18, 2023 Genetron Regains Compliance With Nasdaq Listing Requirement Jan 17, 2023 Yantai LNC Biotechnology to Use Sofie Biosciences Imaging Agent to ID Patients for Theranostic Trial Jan 17, 2023 Leap Therapeutics Merges With Flame Biosciences to Advance Several Precision Oncology Drugs Jan 17, 2023 Elicio Therapeutics to Merge With Angion Biomedica Jan 17, 2023 Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
